Skip to content

Released Dec 4, 2020, after the close

10-Q filed Dec 4, 2020, 65 days after period end · 0001193125-20-310715

Q3 2020 · 10-Q
Revenue$179.00Kno prior Q3 2019 on fileno prior Q2 2020 on file
Net Income-$18.37MN/M vs Q3 2019N/M vs Q2 2020
EPS Diluted-$3.12N/M vs Q3 2019N/M vs Q2 2020
Operating Income-$18,489,000N/M
Operating Cash Flowderived$2,726,000—
Free Cash Flowderived-$2,699,000—
Margins · derived
Operating margin-10329.1%
Net margin-10260.9%

What the release said

The release

Same quarter

MetricQ3 2020Q3 2019
Revenue$179.00K—
Net Income-$18.37M-$13.09M
EPS Diluted-$3.12-$3.05

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR